Home/Filings/4/0001493152-22-017660
4//SEC Filing

Thompson Jaye 4

Accession 0001493152-22-017660

CIK 0001799788other

Filed

Jun 23, 8:00 PM ET

Accepted

Jun 24, 8:14 AM ET

Size

5.6 KB

Accession

0001493152-22-017660

Insider Transaction Report

Form 4
Period: 2022-06-22
Thompson Jaye
VP Clinical & Reg Affairs
Transactions
  • Award

    Stock Options

    2022-06-22+149,818149,818 total
    Exercise: $7.63Exp: 2032-06-22Common Stock (149,818 underlying)
Footnotes (1)
  • [F1]The options vest over time and pursuant to milestones. 3,121 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration.

Documents

1 file

Issuer

Greenwich LifeSciences, Inc.

CIK 0001799788

Entity typeother

Related Parties

1
  • filerCIK 0001476971

Filing Metadata

Form type
4
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 8:14 AM ET
Size
5.6 KB